Robert Fishberg, MD
Cardiovascular Disease · Springfield, NJNPI 1871587345
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,369 of the $93,525 with a category attached, or 65.6%. 45 manufacturers reported payments, led by Amgen at 48.8% of the total. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 577 payments — averaging $162.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$46K
- Ionis Pharmaceuticals, Inc.$14K
- Amarin Pharma, Inc.$12K
- Esperion Therapeutics, Inc.$7K
- Regeneron Healthcare Solutions, Inc.$5K
- Novartis$2K
- plus $7K from 39 others
Across 67 payments — averaging $27,268 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Eli Lilly$323K
- Amgen$243K
- Regeneron$84K
- Kowa Research Institute, Inc.$23K
What the payments were for
- Consulting fees$16,87318%
- Speaking & faculty fees$61,36966%
- Travel & lodging$2,9153%
- Food & beverage$12,00413%
- Education$3640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,525 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 330 | $368,261 |
| XareltoRivaroxaban | 282 | $334,925 |
| Repatha SureclickEvolocumab | 226 | $253,530 |
| EntrestoSacubitril/Valsartan | 133 | $182,015 |
| JardianceEmpagliflozin | 114 | $135,185 |
| FarxigaDapagliflozin Propanediol | 72 | $85,082 |
| MultaqDronedarone Hcl | 41 | $51,808 |
| Praluent PenAlirocumab | 48 | $45,495 |
| LivaloPitavastatin Calcium | 53 | $40,068 |
| VascepaIcosapent Ethyl | 68 | $37,635 |
| KerendiaFinerenone | 40 | $36,658 |
| BrilintaTicagrelor | 36 | $30,082 |
| OzempicSemaglutide | 13 | $22,951 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 32 | $22,418 |
| Icosapent Ethyl | 46 | $17,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $191 | $368,261330 claims |
| Johnson & JohnsonXarelto | $359 | $334,925282 claims |
| NovartisEntresto | $2,484 | $182,015133 claims |
| Boehringer IngelheimJardiance | $491 | $135,185114 claims |
| AstraZenecaFarxiga, Brilinta | $167 | $115,164108 claims |
| Sanofi-aventis U.S. LLCMultaq | $106 | $51,80841 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $17 | $36,66760 claims |
| BayerKerendia | $538 | $36,65840 claims |
| Novo NordiskOzempic | $415 | $22,95113 claims |
| Esperion Therapeutics, Inc.Nexlizet | $7,242 | $17,52821 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $20 | $1,56167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Springfield
- David PowellSpringfield$162K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.